GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » American Oncology Network Inc (OTCPK:AONC) » Definitions » Net Issuance of Preferred Stock

American Oncology Network (American Oncology Network) Net Issuance of Preferred Stock : $0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is American Oncology Network Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

American Oncology Network's net issuance of preferred for the three months ended in Mar. 2024 was $0 Mil. The number is 0, which means that American Oncology Network has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

American Oncology Network's net issuance of preferred for the trailing twelve months (TTM) ended in Mar. 2024 was $0 Mil.

American Oncology Network Net Issuance of Preferred Stock Historical Data

The historical data trend for American Oncology Network's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

American Oncology Network Net Issuance of Preferred Stock Chart

American Oncology Network Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Net Issuance of Preferred Stock
- - - -

American Oncology Network Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Net Issuance of Preferred Stock Get a 7-Day Free Trial - - - - -

American Oncology Network Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

American Oncology Network Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of American Oncology Network's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

American Oncology Network (American Oncology Network) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » American Oncology Network Inc (OTCPK:AONC) » Definitions » Net Issuance of Preferred Stock
Comparable Companies
PIII TOI BTMD AVAH CYH JYNT PNTG SNDA AIRS CCM HCA SAU:4013 SZSE:300015 HKSE:06618 XTER:FRE BKK:BDMS XKLS:5225 BSP:RDOR3 XTER:FME UHS
Traded in Other Exchanges
N/A
Address
10485 NE 6th Street, Unit 3930, Bellevue, WA, USA, 98004
Website
https://www.aoncology.com
American Oncology Network Inc Formerly American Oncology Network LLC is an alliance of physicians and seasoned healthcare leaders who provide comprehensive oncology services through 24 oncology practices located in Arkansas, Louisiana, Indiana, Virginia, Ohio, Nevada, Iowa, Missouri, Washington, North Carolina, Michigan, Maryland, South Carolina, Arizona, and Georgia. The Company also provides expertise in drug procurement and payor contracting, along with practice diversification through centralized laboratory and pathology services, as well as specialty pharmacy services.
Executives
Saba Capital Management, L.p. 10 percent owner 405 LEXINGTON AVENUE, 58TH FLOOR, NEW YORK NY 10174
Boaz Weinstein 10 percent owner 405 LEXINGTON AVENUE, 58TH FLOOR, NEW YORK NY 10174
David H Gould officer: Chief Financial Officer 7370 COLLEGE PARKWAY, SUITE 207, FORT MEYERS FL 33907
Erica Mallon officer: General Counsel 14543 GLOBAL PARKWAY, SUITE 110, FORT MEYERS FL 33913
Shalin Shah director 3402 W DR. MARTIN LUTHER KING JR. BLVD, TAMPA FL 33607
Vipul M Patel director 11704 SE 15TH CIRCLE, OCALA FL 34480
Todd Schonherz director, officer: Chief Executive Officer 14543 GLOBAL PARKWAY, 2ND FLOOR, FORT MEYERS FL 33913
Stephen Divers director, officer: Chief Medical Officer 133 HARMONY PARK CIRCLE, HOT SPRINGS AZ 71913
Vance Wright-browne director 22395 EDGEWATER DRIVE, PORT CHARLOTTE FL 33980
James Stith director ONE LETTERMAN DRIVE, CM200, SAN FRANCISCO CA 94129
Aea Growth Equity Fund Lp 10 percent owner 520 MADISON AVE, 40TH FLOOR, NEW YORK NY 10022
Aea Growth Equity Fund (parallel) Lp 10 percent owner 520 MADISON AVE, 40TH FLOOR, NEW YORK NY 10022
Ravi Yang Sarin director C/O ARES MANAGEMENT LLC, 2000 AVENUE OF THE STARS, 12TH FLOOR, LOS ANGELES CA 90067
Brian R Hoesterey 10 percent owner C/O AEA INVESTORS LP, 666 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10103
Kevin Nazemi director, officer: Chief Executive Officer 10485 NE 6TH ST, UNIT 3930, BELLEVUE WA 98004